After Chardan Capital and William Blair gave Krystal Biotech Inc (NASDAQ: KRYS) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Ritu Baral maintained a Buy rating on Krystal Biotech Inc today. The company’s shares opened today at $43.79.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 23.2% and a 48.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Krystal Biotech Inc with a $67.75 average price target, implying a 54.7% upside from current levels. In a report released today, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Based on Krystal Biotech Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $4.11 million. In comparison, last year the company had a GAAP net loss of $2.28 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Krystal Biotech, Inc. is a gene therapy company, which engages in developing and commercializing treatment for patients suffering from dermatological diseases. It developed a gene therapy platform, which company refer to as the Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes simplex virus 1, or HSV-1, and skin-optimized gene transfer technology, to develop off-the-shelf treatments for dermatological diseases for which company believe there are no known effective treatments. The company was founded by Suma M. Krishnan in December 2017 and is headquartered in Pittsburgh, PA.
